The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation
Open accessAbstract
Inhibitors of BCL-X L , combined with inhibition of the mTOR/4E-BP axis, drive regressions of PIK3CA mutant breast tumors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Proliferation, cell cycle and apoptosis in cancer
Evan, G. I., & Vousden, K. H. (2001) · Nature · doi:10.1038/35077213 · Cited by 2,724 · cited 1×
“Growth signaling and cell cycle pathways have been pharmacologically targeted with some success, but the effectiveness of these strategies has been limited by incomplete and transient therapeutic responses (2, 3).”
BackgroundMolecular mechanisms of mTOR-mediated translational control
Ma, X. M., & Blenis, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2672 · Cited by 2,558
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992 · cited 1×
“For the case of BCL-2/BCLXL inhibitors, these doses are 5- to 12-fold lower than the equivalent doses required to cause dose-limiting thrombocytopenia in human and large animal models, which are important considerations given the dose-limiting toxicities observed in human clinical trials with these and related agents…”
BackgroundTargeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,900
Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Cited by
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Labrie, M., Brugge, J. S., Mills, G. B., & Zervantonakis, I. K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00454-5 · Cited by 369
Fan, F., Liu, P., Bao, R., Chen, J., Zhou, M., Mo, Z., Ma, Y., Liu, H., Zhou, Y., Cai, X., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1547 · Cited by 198
“However, clinical experience has indicated that targeting a single oncoprotein is often not sufficient to achieve desired therapeutic efficacy due to the development of resistance either by functional redundancy of alternative pathways or genetic mutations that enable drug resistance in surviving cancer cells (9, 10).”
BackgroundMerino, D., Whittle, J. R., Vaillant, F., Serrano, A., Gong, J.-N., Giner, G., Maragno, A. L., Chanrion, M., Schneider, E., Pal, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7049 · Cited by 185
Protein translation: biological processes and therapeutic strategies for human diseases
Jia, X., He, X., Huang, C., Li, J., Dong, Z., & Liu, K. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01749-9 · Cited by 185
“134,135 Relatedly, in colorectal cancer, alterations in translation factors, including increased expression levels of eIFs, contribute to enhanced protein synthesis and upregulation of key factors involved in cell proliferation, tumor growth, metastasis, and oxaliplatin resistance.”
BackgroundDysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors
Anderson, G. R., Wardell, S. E., Çakır, M., Yip, C., Ahn, Y.-R., Ali, M., Yllanes, A. P., Chao, C., McDonnell, D. P., & Wood, K. C. (2018) · Nature Communications · doi:10.1038/s41467-018-04033-x · Cited by 146
Self-citation
Metadata
- Authors
- Anderson, G. R., Wardell, S. E., Cakir, M., Crawford, L., Leeds, J. C., Nussbaum, D. P., Shankar, P. S., Soderquist, R. S., Stein, E. M., Tingley, J. P., Winter, P. S., Zieser-Misenheimer, E. K., Alley, H. M., Yllanes, A., Haney, V., Blackwell, K. L., McCall, S. J., McDonnell, D. P., & Wood, K. C.
- Affiliations
- Department of Pharmacology and Cancer Biology, Duke University, Durham, NC 27710, USA.
- Duke University (US)
- Corresponding author
- Wood, Kris C.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-12-14
- Volume
- 8
- Issue
- 369
- Pages
- 369ra175-369ra175
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5626456
- OpenAlex
- W2563571637
- Cited by
- 53
- References
- 57
- Citations by year
- 2025: 4 · 2024: 5 · 2023: 4 · 2022: 10 · 2021: 7 · 2020: 4 · 2019: 7 · 2018: 10 · 2017: 2
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- DukeSpace (Duke University) (submittedVersion, cc-by-nc-nd)
- Funders
- Duke University School of Medicine
- Duke Cancer Institute
- NIH Building Interdisciplinary Research Careers in Women’s Health Program (K12HD043446)
- Golfers Against Cancer Research Award
- Stewart Trust Fellowship
- NSF (DGE-1106401, DGF-1106401)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- PIK3CA mutation, breast cancer, mTOR signaling, 4E-BP, Bcl-xL inhibitors, tumor dependency, combination therapy, PI3K/Akt signaling
- MeSH terms
- Animals, Breast Neoplasms, DNA Mutational Analysis, Female, Humans, Mice, Nude, Mutation, Neoplasm Transplantation, Gene Expression Regulation, Neoplastic, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Combinatorial Chemistry Techniques, MAP Kinase Signaling System, Cell Line, Tumor, bcl-X Protein, Mice, Class I Phosphatidylinositol 3-Kinases, TOR Serine-Threonine Kinases, Molecular Targeted Therapy, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. https://app.cochat.ai/papers/10.1126/scitranslmed.aae0348
- The paper
- Anderson, G. R., Wardell, S. E., Cakir, M., Crawford, L., Leeds, J. C., Nussbaum, D. P., Shankar, P. S., Soderquist, R. S., Stein, E. M., Tingley, J. P., Winter, P. S., Zieser-Misenheimer, E. K., Alley, H. M., Yllanes, A., Haney, V., Blackwell, K. L., McCall, S. J., McDonnell, D. P., & Wood, K. C. (2016). PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aae0348
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.